Engflag

Wikoryl Tablet

Quick links to important sections

Wikoryl Tablet

Wikoryl Tablet_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Wikoryl Tablet

What is Wikoryl Tablet?

Wikoryl Tablet is a multi-ingredient pharmaceutical formulation primarily used to manage symptoms associated with the common cold, influenza, and upper respiratory tract infections. It is categorized as an analgesic, antipyretic, and antihistamine combination therapy.

Composition and Mechanism

The tablet typically contains three active components that work through different pathways to address various symptoms:

  • Paracetamol (Acetaminophen): Acts as an antipyretic to reduce fever and an analgesic to relieve mild to moderate pain, such as headaches or body aches. It works by inhibiting the synthesis of prostaglandins in the central nervous system.
  • Phenylephrine: Functions as a nasal decongestant. It is a sympathomimetic agent that works by narrowing the blood vessels in the nasal passages, which helps to reduce swelling and congestion.
  • Chlorpheniramine Maleate: An antihistamine that helps alleviate allergy-like symptoms. It blocks the action of histamine, a substance in the body that causes watery eyes, sneezing, and a runny nose.

Primary Uses

This medication is designed to provide temporary relief from a broad spectrum of cold and flu symptoms, including:

  • Nasal and sinus congestion
  • Sneezing and runny nose
  • Fever and chills
  • Minor aches and pains
  • Watery or itchy eyes

By combining these ingredients, the formulation aims to address multiple symptoms simultaneously, rather than treating a single symptom in isolation.

What side effects are possible with Wikoryl Tablet?

Wikoryl Tablet: Possible Side Effects and Safety Information

Adverse reactions to this combination medicine are documented in regulatory labeling by frequency and system-organ class, as is standard for pharmaceutical products.

Classification Common Side Effects Potential Serious Adverse Reactions
System Affected Nervous System, Gastrointestinal Hepatobiliary, Immune System, Skin
Reported Effects Drowsiness, dry mouth, dizziness, headache, nausea, or difficulty sleeping. Severe liver damage (hepatotoxicity), severe cutaneous reactions (SCARs), or anaphylaxis.

Common Adverse Reactions

The most frequently reported adverse effects in regulatory documents are generally linked to the antihistamine and decongestant components. These include central nervous system effects such as drowsiness and dizziness, and anticholinergic effects like dry mouth and dry throat. The label also notes the potential for insomnia or nervousness.

Serious Reactions and Organ System Risk

Regulatory warnings emphasize the risk of severe liver damage associated with the Paracetamol (Acetaminophen) component, which is directly related to the total dose consumed over a 24-hour period. Rare but serious adverse reactions documented in official sources include hypersensitivity reactions like anaphylaxis and severe skin eruptions.

Population-Specific Safety Considerations

Official prescribing information includes specific safety notes for certain groups. Older adults may be more susceptible to side effects such as confusion, dizziness, and difficulty urinating. Pediatric patients may exhibit a paradoxical reaction to the antihistamine, such as agitation or excitation, rather than sedation. Furthermore, the combination is contraindicated for individuals with severe hepatic impairment or uncontrolled high blood pressure.

Overdose and Emergency Response

Overdose and When to Seek Help

Suspected overdose of Wikoryl Tablet requires immediate medical attention and contact with emergency services, regardless of whether initial symptoms are mild or absent. This urgent action is required due to the potential for delayed, life-threatening complications as stated in regulatory documents.

Documented Manifestations and Severe Outcomes

Official regulatory information describes overdose beginning with non-specific signs such as nausea, vomiting, diaphoresis, and general malaise. Overdose can progress to severe central nervous system (CNS) effects, including somnolence, agitation, hallucinations, and seizures, alongside anticholinergic signs like dilated pupils and dry mouth.

The most severe outcome documented is acute hepatic necrosis and subsequent acute liver failure, which is the primary life-threatening risk from the Paracetamol component. Furthermore, regulators note the potential for severe hypertensive crisis and cardiac arrhythmias stemming from the decongestant and antihistamine components, necessitating cardiac monitoring.

Required Emergency Procedures

Hospital monitoring is required for any suspected overdose. The specific antidote N-acetylcysteine (NAC) is mandated for the Paracetamol component, administered according to established protocols. Management is otherwise symptomatic and supportive, focused on controlling CNS and cardiovascular manifestations. Patients with pre-existing hepatic impairment are noted to have an increased risk of severe toxicity.

Therapeutic Uses of Wikoryl Tablet

What Wikoryl Tablet Treats: Main Uses and Benefits

The therapeutic scope involves the use of combination ingredients for upper respiratory conditions. This medication is applied across therapeutic domains that involve acute or disruptive symptom patterns. It is commonly used across conditions presenting with acute episodes of the common cold, flu-like syndromes, and seasonal or perennial allergic rhinitis.

The medication helps manage a cluster of symptoms, including fever, headache, minor physical discomfort or body aches, nasal blockage, and the sensation of sinus pressure. Additionally, it is relevant for easing allergy-driven runny nose, frequent sneezing, and itchy/watery eyes. This short-term symptomatic assistance is often used when multiple symptoms occur together and interfere with routine activities.

It is commonly used when symptoms become more disruptive during flare-ups, providing support that helps ease the overall symptom load.

This combination contributes to easing the overall symptom load, which supports patients during episodes of heightened discomfort and assists with maintaining a sense of stability when symptoms are more noticeable, while supporting clearer breathing.

Quick Fact: Relief for Multi-Symptom Discomfort

Property Description
Primary Domain Symptomatic relief of upper respiratory infections and allergies.
Usage Context Acute episodes, recurrent seasonal flare-ups, and multi-symptom presentations.
Main Benefit Supports the patient by easing the overall symptom load and physical discomfort.

Regulatory References

  1. DailyMed (NLM - NIH) labeling

Eligibility and Restrictions for Use

The eligibility for Wikoryl Tablet is strictly defined by regulatory documents based on a patient's pre-existing health status and life stage. Use is permitted for Adults and Children 12 years of age and over who do not have any contraindications.

Contraindicated Populations

Official labeling strictly prohibits use in patients with:

  • Known hypersensitivity or allergy to Paracetamol, Chlorpheniramine Maleate, or Phenylephrine.
  • Severe Active Liver Disease or Severe Hepatic Impairment.
  • Severe Hypertension or Severe Heart Disease.
  • Concurrent or recent use (within the last 14 days) of Monoamine Oxidase Inhibitors (MAOIs).
  • Lower Respiratory Diseases, such as Acute Asthma or Chronic Bronchitis.

Restricted and Conditional Use

The medicine is not recommended for children under 12 years of age. Use requires caution in populations with specific conditions, including non-severe Renal or Hepatic Impairment, Diabetes Mellitus, Closed-Angle Glaucoma, or conditions that cause Urinary Retention (e.g., enlarged prostate).

Pregnancy and Lactation Status

Wikoryl Tablet is generally not recommended for use in pregnant women or lactating mothers due to the presence of its active components, and should only be used if explicitly deemed essential by a healthcare provider.

What should I know about interactions with other medicines?

The official regulatory profile for this combination medicine, containing Paracetamol, Chlorpheniramine Maleate, and Phenylephrine, outlines specific interaction constraints grounded in authoritative government documentation. The profile is structured around mandated prohibitions and cautions concerning additive effects and alterations to drug exposure.

Contraindicated and Prohibited Combinations

Co-administration is formally contraindicated with Monoamine Oxidase Inhibitors (MAOIs), including for 14 days following MAOI cessation, due to the established risk of severe hypertensive crises. Use with other Sympathomimetic Decongestants is also prohibited due to the risk of additive cardiovascular side effects. Furthermore, the co-administration of any other product containing Paracetamol is prohibited to prevent inadvertent overdose and subsequent fatal hepatotoxicity.

Pharmacodynamic and Exposure Cautions

The label notes that Alcohol and CNS Depressants (such as anxiolytics and hypnotics) must be avoided due to the additive CNS depression and excessive drowsiness caused by the Chlorpheniramine component. The Phenylephrine component may reduce the efficacy of Antihypertensive Drugs (including Beta-blockers). The regular, prolonged use of Paracetamol may enhance the anticoagulant effect of Warfarin and other Coumarins, requiring close monitoring. The absorption rate of Paracetamol is officially noted to be increased by agents such as Metoclopramide and reduced by Colestyramine. The elderly population is noted to be more susceptible to the neurological effects of Chlorpheniramine-related interactions.

Mechanism of Action

Wikoryl Tablet functions through the collective pharmacodynamic actions of three distinct chemical entities: paracetamol, phenylephrine, and chlorpheniramine maleate.

Chlorpheniramine maleate acts as a competitive inverse agonist at peripheral histamine H1 receptors. By binding to these receptors, it stabilizes the inactive conformation, preventing the effects of endogenous histamine. This blocks histamine-mediated increases in vascular permeability and vasodilation in target tissues, modulating subsequent fluid extravasation.

Phenylephrine is a direct-acting sympathomimetic amine and a selective agonist of the alpha1-adrenergic receptors predominantly located on vascular smooth muscle cells. Its binding initiates the Gq protein cascade, leading to the activation of phospholipase C, production of inositol trisphosphate ( IP3) and diacylglycerol (DAG), and a resultant increase in intracellular calcium concentration. This molecular event drives the contraction of vascular smooth muscle, causing systemic vasoconstriction, particularly in the microvasculature of the nasal mucosa.

Paracetamol's primary analgesic action is exerted centrally, potentially through the formation of its active metabolite, N-acylphenolamine (AM404), which interacts with TRPV1 receptors and the endocannabinoid system. Its antipyretic mechanism involves the inhibition of prostaglandin synthesis in the central nervous system, likely through the inhibition of COX peroxidase activity in the hypothalamus's thermoregulatory center. This central modulation leads to the resetting of the hypothalamic set point, facilitating heat dissipation via peripheral mechanisms.

Dosage and Administration Information

The use of this fixed-dose oral combination medicine, which contains Paracetamol, Chlorpheniramine Maleate, and Phenylephrine, is defined by administration guidelines intended for short-term symptomatic application. The sole route of administration is oral, meaning the solid tablet form is taken by mouth.

Standard Dosing and Administration

The regimen is structured on an as-needed (PRN) basis, where a dose is administered when symptoms are present. For adults and children 12 years of age and older, the dosing regimen is one to two tablets per dose. This unit dose may be repeated every four to six hours, as needed. Administration for children under 12 years of age is subject to specific guidance.

It is procedurally critical to observe the established maximum intake limit: the total number of tablets taken must not exceed eight tablets within a 24-hour period.

Procedural Instructions

To ensure proper administration, the tablet must be swallowed whole with water. It is instructed that the tablet must not be crushed, chewed, or dissolved before ingestion, as the physical integrity of the dosage form is necessary for correct delivery. Administration timing is not reliant on food intake; the tablet may be taken with or without food.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section provides an overview of key research that evaluated the properties of combination products containing the ingredients found in Wikoryl tablets (typically Paracetamol, Phenylephrine, and Chlorpheniramine). Studies examined various aspects of these fixed-dose combinations (FDCs), focusing on the symptomatic relief of the common cold.

Key Clinical Studies

Studies have been conducted to evaluate the effects of the three-drug combination compared to a placebo in adults and adolescents suffering from common cold or flu-like symptoms. These trials focused on measuring changes in total symptom scores (TSS) over short periods, usually less than a week.

  • Placebo-Controlled Trials: A randomized, placebo-controlled trial involving the combination reported a significantly greater reduction in overall symptom scores in the treatment group compared to the placebo group. The study primarily evaluated symptom relief, not the duration of the illness.
  • Post-Marketing Surveillance Studies: Several studies have been conducted to examine the use of this fixed combination in adults and pediatric subgroups (children aged 6 and older). These studies focused on assessing changes in symptom severity, with most patients reporting symptomatic changes within the first three days of treatment.

Long-Term Research and Subgroups

Studies examined the long-term properties of the combination by assessing follow-up periods. Research included studies that documented outcomes for participants representing diverse health profiles.

  • Subgroup Findings: Research also explored findings in specific populations, with studies documenting outcomes for participants with co-existing conditions. These evaluations aim to provide data on how the combination is used in the wider patient population.
  • Combination Therapies: Studies evaluated the profile of combining this treatment with other agents. Research also focused on data points when the drug was co-administered with other agents, which is relevant to understanding the product’s overall use.

Key Studies & References Post marketing surveillance study (PMS) to assess the safety of fixed-dose combination therapy of paracetamol, phenylephrine, and chlorpheniramine maleate for the symptomatic treatment of common cold in Indian adults

Frequently Asked Questions (FAQ)

Common questions about Wikoryl Tablet (FAQ)

Q: How quickly does Wikoryl Tablet start working after it is taken?

A: Official information indicates that the three components of Wikoryl Tablet have different onsets of action. The analgesic and fever-reducing component (Paracetamol) is generally reported to reach its highest concentration in the bloodstream within a specific timeframe, often between 10 to 60 minutes after oral administration.

Q: Is it common for people to feel drowsy after taking Wikoryl Tablet?

A: Yes, official labeling states that drowsiness may occur. This is attributed to the presence of an antihistamine component in the combination medicine. Official guidance suggests exercising caution when undertaking activities that require full mental alertness.

Q: Does Wikoryl Tablet cause any issues if mixed with alcohol?

A: Regulatory documents explicitly warn that alcohol must be avoided when using this medication. Combining the tablet with alcohol may increase the risk of drowsiness due to additive central nervous system depression. Furthermore, it may also increase the risk of severe liver damage associated with the paracetamol component.

Q: For how long can someone expect the effects of Wikoryl Tablet to last?

A: The dosing interval is defined by the product's official labeling, stating that a dose may be repeated every four to six hours. This interval describes the typical timeframe for when the symptomatic relief provided by the tablet is expected to last.

Q: Why do some people say they feel nervous or restless after taking this tablet?

A: Official warnings note that feelings of nervousness, restlessness, or sleeplessness may occur. These effects are generally linked to the presence of the decongestant component, which is a known effect of this class of ingredients.

Q: How is Wikoryl Tablet cleared from the body?

A: Like most medications, the components of Wikoryl Tablet are broken down and processed by the body. Regulatory information describes that the main analgesic and fever-reducing component is largely metabolized in the liver and subsequently eliminated through the kidneys (excretion in the urine).

Q: Is there a warning about taking Wikoryl Tablet with other cold or flu preparations?

A: Yes, the official labeling includes a specific warning against combining this tablet with certain other medicines. It is officially prohibited to take Wikoryl Tablet with any other products that contain paracetamol or any other decongestants classified as sympathomimetics.

Q: Does Wikoryl Tablet contain an antihistamine component?

A: Yes, Wikoryl Tablet is a combination medicine that contains Chlorpheniramine Maleate. According to official documents, the purpose of this ingredient is described as providing the actions of an antihistamine to help with symptoms like sneezing and runny nose.

Q: What kind of official warnings exist about using Wikoryl Tablet for more than a few days?

A: The product is officially intended for temporary relief of cold symptoms. Official instructions advise stopping use if pain or nasal congestion gets worse or lasts for more than 7 days.

Q: Is there any information about Wikoryl Tablet use during pregnancy?

A: Yes, the official label includes guidance for this life stage. The official warning advises consulting a health professional before use if an individual is pregnant or breastfeeding.

Q: Are there any specific foods that should be avoided when taking Wikoryl Tablet?

A: Official drug sources do not list specific foods that must be strictly avoided when taking Wikoryl Tablet. However, a caution exists regarding the consumption of alcohol and excessive amounts of caffeine-containing foods or beverages due to the potential for undesirable additive effects.

Q: Can people who have liver problems use Wikoryl Tablet?

A: Official instructions advise that use is prohibited for individuals diagnosed with severe hepatic impairment (severe liver damage). For individuals with pre-existing liver disease that is not classified as severe, the label indicates consulting a health professional is advised before use.

Q: Is Wikoryl Tablet described as being habit-forming in official documents?

A: The active ingredients in Wikoryl Tablet are generally not categorized as controlled substances. Official drug sources, therefore, do not include specific warnings or descriptions of this combination product as having the potential to be habit-forming.

Q: Is it possible for a skin rash to develop while using Wikoryl Tablet?

A: The product includes an allergy alert indicating that a severe skin reaction may occur, and official safety profiles document rashes as a potential symptom of allergic or hypersensitivity reactions. The product label advises stopping use and seeking medical attention immediately if a skin reaction develops.

Q: What should be done if someone accidentally takes too much Wikoryl Tablet?

A: Official instructions state that in the event of an accidental overdose, seeking immediate medical help or contacting a Poison Control Center is critical. This action is advised even if the individual does not yet feel any symptoms of overdose.

Q: Can Wikoryl Tablet affect my ability to drive or operate machinery?

A: Yes, official warnings advise that caution should be exercised when driving a motor vehicle or operating machinery. This is a mandatory precaution because the antihistamine component in the medicine can cause drowsiness.

Q: Does official information mention Wikoryl Tablet being used for allergy symptoms?

A: Yes, the officially defined uses for the medication include temporary relief for symptoms associated with hay fever and other upper respiratory allergies. The antihistamine component is key to addressing these specific allergy-related symptoms.

Q: Is Wikoryl Tablet known to cause stomach upset?

A: The safety profile for the tablet documents the potential for gastrointestinal (GI) disturbances. Reported effects include common side effects such as nausea and vomiting.

Q: What does the patient leaflet say about overdose symptoms for Wikoryl Tablet?

A: The primary risk highlighted in the overdose warnings relates to the paracetamol component. Official documents advise that taking more than the recommended amount can lead to severe liver damage, which can be fatal. The official warning indicates this risk is present even if symptoms are not immediately apparent.

Q: What are the known components that can cause allergic reactions in Wikoryl Tablet?

A: Official allergy alerts advise against using the product if a person is allergic to the medicine or any of its ingredients. This refers to all components of the tablet, including the three active ingredients (Paracetamol, Chlorpheniramine Maleate, Phenylephrine) and any inactive substances used in the formulation.

How should Wikoryl Tablet be stored and disposed of?

Storage and Disposal of Wikoryl Tablet

The storage requirements for Wikoryl Tablet are defined by regulatory authorities to ensure product quality. The medicine must be stored at room temperature, typically designated as below 30°C or 25°C, and kept in its original container with the lid tightly closed.

Required Conditions

The tablets must be protected from moisture, excessive heat, and direct light. A mandatory safety rule is to always keep the medicine out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Wikoryl Tablet must be disposed of properly. Follow the specific instructions provided on the packaging and adhere to local regulations for the disposal of pharmaceuticals. Do not dispose of the tablets in wastewater or household trash without first following government-approved preparation guidelines, such as utilizing an authorized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Wikoryl Tablet found in:

A-Z Index: